Doximity (NYSE:DOCS) Director Kira Scherer Wampler Sells 2,000 Shares of Company Stock

Doximity, Inc. (NYSE:DOCS) Director Kira Wampler sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $32.89, for a total value of $65,780.00. Following the completion of the sale, the director owned 27,923 shares in the company, valued at $918,387.47. This represents a 6.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kira Scherer Wampler also recently made the following trade(s):

• On Thursday, October 1st, Kira Wampler sold 2,000 shares of Doximity stock. The shares were sold at an average price of $28.91, for a total value of $57,820.00.
• On Tuesday, August 25th, Kira Wampler sold 2,000 shares of Doximity stock. The stock was sold at an average price of $24.95, for a total value of $49,900.00.

Doximity Stock Up 6.3%

Shares of DOCS stock traded up $2.04 during trading on Wednesday, reaching $34.64. 2,999,775 shares of the company’s stock were exchanged, compared to its average volume of 2,855,932. The stock has a market capitalization of $6.17 billion, a PE ratio of 35.82, a PEG ratio of 25.50 and a beta of 1.29. Doximity, Inc. has a twelve month low of $17.15 and a twelve month high of $66.11. The firm’s fifty day moving average price is $28.78 and its 200-day moving average price is $25.59.

Doximity (NYSE:DOCS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.13. Doximity had a return on equity of 18.06% and a net margin of 25.48%. The business had revenue of $156.62 million for the quarter. During the same quarter last year, the company posted $0.36 EPS. The firm’s revenue was up 7.3% on a year-over-year basis. As a group, analysts anticipate that Doximity, Inc. will post 0.74 EPS for the current fiscal year.

Doximity News Roundup

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Valuation commentary points to potential upside: one article says a model sees about 53% upside, and another describes Doximity as roughly 3% undervalued following its DoseCheck and UpToDate rollout. These are model-based assessments, not guarantees or new company guidance. Earnings To Watch: Doximity Inc (DOCS) Q2 2027 — GF Value Sees 53% Upside Doximity Could Be 3% Undervalued Following DoseCheck And UpToDate Rollout
• Neutral Sentiment: Investors are looking ahead to Doximity’s fiscal Q2 2027 results for the quarter ended September 2026. The articles preview Wall Street estimates and key metrics but do not report results, so they provide no confirmed earnings surprise. Q2 Performance and Wall Street Estimates
• Negative Sentiment: Several law firms are publicizing a pending securities class action and a November 16, 2026 lead-plaintiff deadline. The complaint alleges Doximity overstated the Newsfeed product’s contribution to revenue growth and its competitive position; these are allegations, not established findings. Litigation can add uncertainty and reputational risk. DOCS Securities Class Action Deadline Alert

Institutional Investors Weigh In On Doximity

Several institutional investors have recently made changes to their positions in DOCS. M&G PLC increased its stake in Doximity by 96.4% during the 3rd quarter. M&G PLC now owns 577,196 shares of the company’s stock worth $16,161,000 after acquiring an additional 283,296 shares during the period. Fulcrum Asset Management LLP lifted its position in shares of Doximity by 17,401.8% during the 3rd quarter. Fulcrum Asset Management LLP now owns 66,857 shares of the company’s stock valued at $1,773,000 after acquiring an additional 66,475 shares during the period. Brighton Jones LLC bought a new stake in shares of Doximity during the 3rd quarter valued at $239,000. StoneX Group Inc. acquired a new stake in shares of Doximity during the 3rd quarter worth $206,000. Finally, Parallel Advisors LLC grew its holdings in shares of Doximity by 241.4% during the 3rd quarter. Parallel Advisors LLC now owns 8,436 shares of the company’s stock worth $239,000 after purchasing an additional 5,965 shares in the last quarter. 87.19% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. BMO Capital Markets reiterated a “market perform” rating and set a $30.00 target price on shares of Doximity in a research note on Friday, August 7th. Wolfe Research raised Doximity to an “outperform” rating in a report on Thursday, August 13th. Wells Fargo & Company cut Doximity from an “equal weight” rating to an “underweight” rating and set a $18.00 price objective on the stock. in a research report on Monday, August 10th. Freedom Capital downgraded Doximity from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. Finally, Piper Sandler reissued an “overweight” rating and issued a $47.00 target price (up from $42.00) on shares of Doximity in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Doximity currently has an average rating of “Hold” and an average target price of $30.73.

Doximity Company Profile

Doximity, Inc operates a digital platform designed for medical professionals in the United States. Its network connects physicians, nurse practitioners, physician assistants, pharmacists and other healthcare professionals, providing tools for professional communication, collaboration and career development.

The company offers services including secure messaging, telehealth, digital faxing, physician scheduling and professional networking. Doximity also provides medical news and educational content, as well as recruiting and job-search resources for healthcare professionals.

Doximity generates additional revenue through digital marketing and engagement solutions for pharmaceutical companies, healthcare organizations and health systems.